IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC (“Covenant Animal Health”).
Related news for (IGXT)
- IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
- IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
- IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
- IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
- IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives